$599
Basal Insulin, Bolus Insulin, Glucose Monitoring, Other, SGLT2i, Topics

AZ Launches DTP Platform; Biolinq Shine Receives De Novo Classification; Amgen Expands US Manufacturing; Fractyl REMAIN-1 Results; Sanofi Expands Insulin Savings

A series of cardiometabolic-related news items has been observed from AstraZeneca, Biolinq, Amgen, and Fractyl Health. Below, FENIX provides highlights and insights for the respective news items. 

This content is for Read Less members only.
Register
Already a member? Log in here
OR
Return to Home